BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Long J, Lin J, Wang A, Wu L, Zheng Y, Yang X, Wan X, Xu H, Chen S, Zhao H. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017;10:146. [PMID: 28774337 DOI: 10.1186/s13045-017-0511-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Zhao H. Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies. Hepatobiliary Surg Nutr 2020;9:348-9. [PMID: 32509826 DOI: 10.21037/hbsn.2019.10.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Katz H, Biglow L, Alsharedi M. Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies. J Gastrointest Cancer 2020;51:611-9. [PMID: 31028537 DOI: 10.1007/s12029-019-00243-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
3 Sun HY, Du ST, Li YY, Deng GT, Zeng FR. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 75-89 [DOI: 10.4251/wjgo.v14.i1.75] [Reference Citation Analysis]
4 Nie K, Zheng Z, Wen Y, Shi L, Xu S, Wang X, Zhou Y, Fu B, Li X, Deng Z, Pan J, Jiang X, Jiang K, Yan Y, Zhuang K, Huang W, Liu F, Li P. Construction and validation of a TP53-associated immune prognostic model for gastric cancer. Genomics 2020;112:4788-95. [PMID: 32858135 DOI: 10.1016/j.ygeno.2020.08.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Li D, Yu T, Han J, Xu X, Wu J, Song W, Liu G, Zhu H, Zeng Z. Prognostic Value and Immunological Role of KIFC1 in Hepatocellular Carcinoma. Front Mol Biosci 2022;8:799651. [DOI: 10.3389/fmolb.2021.799651] [Reference Citation Analysis]
6 Thangamathesvaran L, Shah R, Verma R, Mahmoud O. Immune checkpoint inhibitors and radiotherapy-concept and review of current literature. Ann Transl Med 2018;6:155. [PMID: 29862244 DOI: 10.21037/atm.2018.03.09] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
7 Yi M, Qin S, Zhao W, Yu S, Chu Q, Wu K. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol 2018;7:28. [PMID: 30473928 DOI: 10.1186/s40164-018-0120-y] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 12.8] [Reference Citation Analysis]
8 Li H, Lu H, Cui W, Huang Y, Jin X. A TP53-based immune prognostic model for muscle-invasive bladder cancer. Aging (Albany NY) 2020;13:1929-46. [PMID: 33323544 DOI: 10.18632/aging.202150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Chascsa DM, Rakela J. Knowns and Unknowns: the Safety and Efficacy of Cancer Immunotherapy in Chronic Liver Disease. Curr Hepatology Rep 2018;17:153-5. [DOI: 10.1007/s11901-018-0408-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Jesus VHF, Felismino TC, Barros E Silva MJ, Souza E Silva V, Riechelmann RP. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies. Clinics (Sao Paulo) 2018;73:e510s. [PMID: 30365605 DOI: 10.6061/clinics/2018/e510s] [Reference Citation Analysis]
11 Hu X, Zhu H, Chen B, He X, Shen Y, Zhang X, Chen W, Liu X, Xu Y, Xu X. Tubulin Alpha 1b Is Associated with the Immune Cell Infiltration and the Response of HCC Patients to Immunotherapy. Diagnostics 2022;12:858. [DOI: 10.3390/diagnostics12040858] [Reference Citation Analysis]
12 Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H. Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018;2:289-303. [PMID: 30003192 DOI: 10.1002/ags3.12180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
13 Guseva LN. [Nitritometric determination of allacyl]. Farmatsiia. 1969;18:43-45. [PMID: 5793409 DOI: 10.1186/s13045-017-0551-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
14 Zhang C, Chong X, Jiang F, Gao J, Chen Y, Jia K, Fan M, Liu X, An J, Li J, Zhang X, Shen L. Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. J Extracell Vesicles 2022;11:e12209. [PMID: 35362262 DOI: 10.1002/jev2.12209] [Reference Citation Analysis]
15 Wang A, Li Z, Wang M, Jia S, Chen J, Ji K, Ji X, Zong X, Wu X, Zhang J, Li Z, Zhang L, Hu Y, Bu Z, Zheng Q, Ji J. Molecular characteristics of synchronous multiple gastric cancer. Theranostics 2020;10:5489-500. [PMID: 32373223 DOI: 10.7150/thno.42814] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Zhang Q, Cheng L, Qin Y, Kong L, Shi X, Hu J, Li L, Ding Z, Wang T, Shen J, Yang Y, Yu L, Liu B, Liu C, Qian X. SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in gastrointestinal cancers. Clin Transl Immunology 2021;10:e1347. [PMID: 34729183 DOI: 10.1002/cti2.1347] [Reference Citation Analysis]
17 Zhu N, Weng S, Wang J, Chen J, Yu L, Fang X, Yuan Y. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. J Cancer Res Clin Oncol 2019;145:3021-36. [PMID: 31617075 DOI: 10.1007/s00432-019-03044-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
18 Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, Mao Y, Sang X, Seery S, Zhao H. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol 2019;12:42. [PMID: 31014381 DOI: 10.1186/s13045-019-0730-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
19 Bai X, Yi M, Jiao Y, Chu Q, Wu K. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor. Onco Targets Ther 2019;12:9527-38. [PMID: 31807028 DOI: 10.2147/OTT.S224013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
20 Jiang X, Jiang Z, Xiang L, Chen X, Wu J, Jiang Z. Identification of a two-gene prognostic model associated with cytolytic activity for colon cancer. Cancer Cell Int 2021;21:95. [PMID: 33557848 DOI: 10.1186/s12935-021-01782-6] [Reference Citation Analysis]
21 Long J, Zhang L, Wan X, Lin J, Bai Y, Xu W, Xiong J, Zhao H. A four-gene-based prognostic model predicts overall survival in patients with hepatocellular carcinoma. J Cell Mol Med. 2018;22:5928-5938. [PMID: 30247807 DOI: 10.1111/jcmm.13863] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
22 Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immune checkpoint blockers for cancer therapy. Oncoimmunology 2017;6:e1373237. [PMID: 29147629 DOI: 10.1080/2162402X.2017.1373237] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
23 Long J, Wang D, Wang A, Chen P, Lin Y, Bian J, Yang X, Zheng M, Zhang H, Zheng Y, Sang X, Zhao H. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Med 2022;14:20. [PMID: 35197093 DOI: 10.1186/s13073-022-01024-y] [Reference Citation Analysis]
24 Park JJ, Arafath S, Kumar ST, Sharma R, Dixit D. Managing toxicities associated with immune checkpoint inhibitors. JAAPA 2021;34:32-9. [PMID: 34031312 DOI: 10.1097/01.JAA.0000735760.65235.3c] [Reference Citation Analysis]
25 He Y, Liu ZX, Jiang ZH, Wang XS. Identification of genomic features associated with immunotherapy response in gastrointestinal cancers. World J Gastrointest Oncol 2019; 11(4): 270-280 [PMID: 31040893 DOI: 10.4251/wjgo.v11.i4.270] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Hu B, Niu L, Jiang Z, Xu S, Hu Y, Cao K. LncRNA XLOC_003810 promotes T cell activation and inhibits PD-1/PD-L1 expression in patients with myasthenia gravis-related thymoma. Scand J Immunol 2020;92:e12886. [PMID: 32243615 DOI: 10.1111/sji.12886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Khoshghamat N, Jafari N, Moetamani-Ahmadi M, Khalili-Tanha G, Khajavi Rad MH, Sahebdel S, Khalili-Tanha N, Soleimanpour S, Khazaei M, Hassanian SM, Ferns GA, Avan A. Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers. Pathol Res Pract 2021;220:153390. [PMID: 33640713 DOI: 10.1016/j.prp.2021.153390] [Reference Citation Analysis]
28 Zou H, Tuhin IJ, Monty MA, Luo S, Shao J, Yan Z, Yu L. Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments. Hum Gene Ther 2020;31:1074-85. [PMID: 32390483 DOI: 10.1089/hum.2019.169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Zhang C, Chen Z, Chong X, Chen Y, Wang Z, Yu R, Sun T, Chen X, Shao Y, Zhang X, Gao J, Shen L. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. Clin Transl Med 2020;10:e254. [PMID: 33377634 DOI: 10.1002/ctm2.254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sun Y, Li L, Yao W, Liu X, Yang Y, Ma B, Xue D. USH2A Mutation is Associated With Tumor Mutation Burden and Antitumor Immunity in Patients With Colon Adenocarcinoma. Front Genet 2021;12:762160. [PMID: 34795697 DOI: 10.3389/fgene.2021.762160] [Reference Citation Analysis]
31 Montinaro A, Walczak H. Sterile Inflammation Fuels Gastric Cancer. Immunity 2018;48:481-3. [PMID: 29562199 DOI: 10.1016/j.immuni.2018.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Trommer M, Yeo SY, Persigehl T, Bunck A, Grüll H, Schlaak M, Theurich S, von Bergwelt-Baildon M, Morgenthaler J, Herter JM, Celik E, Marnitz S, Baues C. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. Front Pharmacol 2019;10:511. [PMID: 31156434 DOI: 10.3389/fphar.2019.00511] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
33 Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S. Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 2019;8:29. [PMID: 31737426 DOI: 10.1186/s40164-019-0154-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
34 Deng T, Hu B, Jin C, Tong Y, Zhao J, Shi Z, Zhang T, Deng L, Sun Z, Chen G, Wang Y. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma. J Cell Mol Med 2021;25:6618-33. [PMID: 34085405 DOI: 10.1111/jcmm.16666] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
35 Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 2018;7:17. [PMID: 30087805 DOI: 10.1186/s40164-018-0109-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
36 Kang YB, Cai Y. Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. World J Gastroenterol 2021;27:5362-75. [PMID: 34539138 DOI: 10.3748/wjg.v27.i32.5362] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Shang J, Han X, Zha H, Tao H, Li X, Yuan F, Chen G, Wang L, Ma J, Hu Y. Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade. Front Oncol 2021;11:585271. [PMID: 33718140 DOI: 10.3389/fonc.2021.585271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. Integr Cancer Ther 2019;18:1534735419876351. [PMID: 31517538 DOI: 10.1177/1534735419876351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
39 Zhang Q, Wang Z, Yu X, Zhang M, Zheng Q, He Y, Guo W. Immune Subtypes Based on Immune-Related lncRNA: Differential Prognostic Mechanism of Pancreatic Cancer. Front Cell Dev Biol 2021;9:698296. [PMID: 34307375 DOI: 10.3389/fcell.2021.698296] [Reference Citation Analysis]
40 Gouveia AG, Chan DCW, Hoskin PJ, Marta GN, Trippa F, Maranzano E, Chow E, Silva MF. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review. Radiother Oncol 2021;163:55-67. [PMID: 34333087 DOI: 10.1016/j.radonc.2021.07.022] [Reference Citation Analysis]
41 Morse MA, Hochster H, Benson A. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. Oncologist. 2020;25:33-45. [PMID: 31383813 DOI: 10.1634/theoncologist.2019-0176] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
42 Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG. Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys 2018;101:1222-5. [PMID: 29859792 DOI: 10.1016/j.ijrobp.2018.04.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
43 Long J, Wang D, Yang X, Wang A, Lin Y, Zheng M, Zhang H, Sang X, Wang H, Hu K, Zhao H. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. BMC Med 2021;19:154. [PMID: 34284787 DOI: 10.1186/s12916-021-02031-3] [Reference Citation Analysis]
44 Long J, Huang S, Bai Y, Mao J, Wang A, Lin Y, Yang X, Wang D, Lin J, Bian J, Yang X, Sang X, Wang X, Zhao H. Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis. Brief Bioinform 2021;22:bbaa224. [PMID: 33051665 DOI: 10.1093/bib/bbaa224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
45 Wu F, Chen W, Kang X, Jin L, Bai J, Zhang H, Zhang X. A seven-nuclear receptor-based prognostic signature in breast cancer. Clin Transl Oncol 2021;23:1292-303. [PMID: 33210236 DOI: 10.1007/s12094-020-02517-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60. [PMID: 30925919 DOI: 10.1186/s12943-019-0974-6] [Cited by in Crossref: 104] [Cited by in F6Publishing: 115] [Article Influence: 34.7] [Reference Citation Analysis]
47 Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N. Lenvatinib for the treatment of renal cell carcinoma. Expert Opin Investig Drugs. 2018;27:507-512. [PMID: 29718721 DOI: 10.1080/13543784.2018.1472235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
48 Yi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, Chu Q, Wu K. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11:47. [PMID: 29580257 DOI: 10.1186/s13045-018-0592-6] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 16.3] [Reference Citation Analysis]
49 Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, Wang S, Wang Z, Li Y, Chen Y, He Q, Chen S, Yao H, Liu Z, Tang Z, Yao Y, Pei D, Liu P, Zhang X, Zhang Z, Cui S, Chen R, Li P. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol 2019;12:18. [PMID: 30777106 DOI: 10.1186/s13045-019-0704-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
50 Verma V, Sharma G, Singh A. Immunotherapy in extensive small cell lung cancer. Exp Hematol Oncol 2019;8:5. [PMID: 30740266 DOI: 10.1186/s40164-019-0129-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
51 Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol 2019;12:98. [PMID: 31521196 DOI: 10.1186/s13045-019-0784-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
52 Long J, Wang A, Bai Y, Lin J, Yang X, Wang D, Yang X, Jiang Y, Zhao H. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019;42:363-374. [PMID: 30885723 DOI: 10.1016/j.ebiom.2019.03.022] [Cited by in Crossref: 73] [Cited by in F6Publishing: 84] [Article Influence: 24.3] [Reference Citation Analysis]